Literature DB >> 2172463

N-methyl-D-aspartate-sensitive glutamate receptors induce calcium-mediated arachidonic acid release in primary cultures of cerebellar granule cells.

J W Lazarewicz1, J T Wroblewski, E Costa.   

Abstract

In primary cultures of cerebellar granule cells, glutamate, aspartate, and N-methyl-D-aspartate (NMDA) induced a dose-dependent release of [3H]arachidonic acid ([3H]AA) which was selective for these agonists and was inhibited by NMDA receptor antagonists. The agonist-induced [3H]AA release was reduced by quinacrine at concentrations that inhibited phospholipase A2 (PLA2) but affected neither the activity of phospholipase C (PLC) nor the hydrolysis of phosphoinositides induced by glutamate or quisqualate. Thus, the increased formation of AA was due to the receptor-mediated activation of PLA2 rather than to the action of PLC followed by diacylglycerol lipase. The receptor-mediated [3H]AA release was dependent on the presence of extracellular Ca2+ and was mimicked by the Ca2+ ionophore ionomycin. Pretreatment of granule cells with either pertussis or cholera toxin failed to inhibit the receptor-mediated [3H]AA release. Hence, in cerebellar granule cells, the stimulation of NMDA-sensitive glutamate receptors leads to the activation of PLA2 that is mediated by Ca2+ ions entering through the cationic channels functioning as effectors of NMDA receptors. A coupling through a toxin-sensitive GTP-binding protein can be excluded.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2172463     DOI: 10.1111/j.1471-4159.1990.tb05771.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  20 in total

Review 1.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

2.  Nitric oxide synthase inhibitors do not attenuate diacylglycerol or monoacylglycerol lipase activities in synaptoneurosomes.

Authors:  A A Farooqui; L A Horrocks
Journal:  Neurochem Res       Date:  1997-10       Impact factor: 3.996

Review 3.  Glutamatergic synaptic dysfunction in hyperammonemic syndromes.

Authors:  V L Rao; C R Murthy; R F Butterworth
Journal:  Metab Brain Dis       Date:  1992-03       Impact factor: 3.584

4.  Region-specific and calcium-dependent increase in dialysate choline levels by NMDA.

Authors:  A Zapata; J L Capdevila; R Trullas
Journal:  J Neurosci       Date:  1998-05-15       Impact factor: 6.167

Review 5.  Phospholipases A2 in ischemic and toxic brain injury.

Authors:  A Sapirstein; J V Bonventre
Journal:  Neurochem Res       Date:  2000-05       Impact factor: 3.996

6.  Mitochondrial dysfunction and lipid peroxidation in rat frontal cortex by chronic NMDA administration can be partially prevented by lithium treatment.

Authors:  Helena K Kim; Cameron Isaacs-Trepanier; Nika Elmi; Stanley I Rapoport; Ana C Andreazza
Journal:  J Psychiatr Res       Date:  2016-02-06       Impact factor: 4.791

Review 7.  Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain.

Authors:  Kenneth I Strauss
Journal:  Brain Behav Immun       Date:  2007-11-08       Impact factor: 7.217

8.  Oxidative mechanisms involved in kainate-induced cytotoxicity in cortical neurons.

Authors:  Y Cheng; A Y Sun
Journal:  Neurochem Res       Date:  1994-12       Impact factor: 3.996

9.  Cytosolic phospholipase A2 alpha inhibition prevents neuronal NMDA receptor-stimulated arachidonic acid mobilization and prostaglandin production but not subsequent cell death.

Authors:  Ava L Taylor; Joseph V Bonventre; Tracy F Uliasz; James A Hewett; Sandra J Hewett
Journal:  J Neurochem       Date:  2008-06-28       Impact factor: 5.372

10.  Regulation of N-methyl-D-aspartate receptor-mediated calcium transport and norepinephrine release in rat hippocampus synaptosomes by polyamines.

Authors:  F Siddiqui; Z Iqbal
Journal:  Neurochem Res       Date:  1994-11       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.